Historical Stock Chart
6 Months : From Jun 2019 to Dec 2019
By Josh Beckerman
Switzerland-based biotechnology company ADC Therapeutics SA has filed for an initial public offering.
ADC focuses on hematological malignancies and solid tumors.
The company plans to trade on the New York Stock Exchange under symbol ADCT. The filing lists an amount of $150 million.
Auven Therapeutics owns 42.7% stake of ADC. AstraZeneca PLC (AZN) owns 7.1%.
Write to Josh Beckerman at email@example.com
(END) Dow Jones Newswires
September 06, 2019 20:11 ET (00:11 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.